{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS-mutant+Colorectal+Cancer+%28CRC%29", "query": { "condition": "KRAS-mutant Colorectal Cancer (CRC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS-mutant+Colorectal+Cancer+%28CRC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T10:46:38.316Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00813605", "title": "QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI", "type": "OTHER" }, { "name": "AMG 655", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "AMG 479", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-03", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2016-10-27", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 28, "location_summary": "Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00813605" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" }, { "nct_id": "NCT07594067", "title": "TCR1188-ABC Cells in KRAS-mutated Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "TCR1188-ABC cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine + Cyclophosphamide combination", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-07", "completion_date": "2042-07", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07594067" }, { "nct_id": "NCT07349537", "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "PDAC", "CRC", "NSCLC", "Pancreatic Cancer", "Lung Cancer (NSCLC)", "Advanced Solid Tumors" ], "interventions": [ { "name": "RMC-5127", "type": "DRUG" }, { "name": "daraxonrasib", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 574, "start_date": "2026-01-08", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 5, "location_summary": "Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349537" }, { "nct_id": "NCT03981614", "title": "Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Unresectable Carcinoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2019-10-29", "completion_date": "2024-07-02", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Wichita, Kansas + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981614" }, { "nct_id": "NCT07629960", "title": "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Neoplasms", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "BLU-924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2026-06-30", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07629960" }, { "nct_id": "NCT06024174", "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986466", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-11-09", "completion_date": "2024-05-13", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 4, "location_summary": "Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Athens", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06024174" }, { "nct_id": "NCT04699188", "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12C Mutant Solid Tumors", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Colorectal", "Cancer of Lung", "Cancer of the Lung", "Lung Cancer", "Neoplasms, Lung", "Neoplasms, Pulmonary", "Pulmonary Cancer", "Pulmonary Neoplasms" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 344, "start_date": "2021-02-24", "completion_date": "2027-01-25", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699188" }, { "nct_id": "NCT06973564", "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "JAB-23E73", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-05-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 4, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973564" }, { "nct_id": "NCT07458347", "title": "A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS-mutant Non-small Cell Lung Cancer (NSCLC)", "KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)", "KRAS-mutant Colorectal Cancer (CRC)", "Other KRAS-mutant Solid Tumors" ], "interventions": [ { "name": "KST-6051", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kestrel Therapeutics, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2026-04-21", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-25T10:46:38.316Z", "location_count": 8, "location_summary": "Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07458347" } ] }